The goal of this study was to use dose-intensity analyses of published Ewing's sarcoma and osteogenic sarcoma trials to determine which agents were most closely associated with a favorable response. The percentage of patients with more than 90 % tumor necrosis following neoadjuvant chemo-therapy was the end point for analysis of osteogenic sarcoma trials, and disease-free survival and percentage of patients with distant-only relapse were the end points for analysis of Ewing's sarcoma trials. The data were analyzed using logis-tic regression analysis to circumvent the distortion of univariate analysis resulting from the correlation between doxorubicin dose intensity and the dose intensity of other agents. Our analysis suggests that...
Objectives: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intend...
Purpose: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven ...
Objective: In this study, we describe experiences with gemcitabine–docetaxel combination therapy as ...
PURPOSE: To analyze the impacts of chemotherapeutic agent exposures on the development of secondary ...
Introduction: osteosarcoma is the most common primary bone tumor in children and young adults and ap...
Full list of author information is available at the end of the articlesystemic cancer therapy for ha...
Contains fulltext : 196658.pdf (publisher's version ) (Open Access)INTRODUCTION: A...
Background Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisp...
Dose intensity and prognosis in the neoadjuvant chemotherapy of osteosarcoma. A retrospective analys...
Dose intensity and prognosis in neoadjuvant chemotherapy for osteosarcoma - A retrospective analysi
Background: A dose response relationship for doxorubictn and cyclophosphamide has been suggested. In...
Purpose: The aim of this study was to compare the results in terms of histologic response to primary...
PURPOSE: The aim of this study was to compare the results in terms of histologic response to prim...
Introduction: osteosarcoma is the most common primary bone tumor in children and young adults and ap...
Objectives: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intend...
Objectives: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intend...
Purpose: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven ...
Objective: In this study, we describe experiences with gemcitabine–docetaxel combination therapy as ...
PURPOSE: To analyze the impacts of chemotherapeutic agent exposures on the development of secondary ...
Introduction: osteosarcoma is the most common primary bone tumor in children and young adults and ap...
Full list of author information is available at the end of the articlesystemic cancer therapy for ha...
Contains fulltext : 196658.pdf (publisher's version ) (Open Access)INTRODUCTION: A...
Background Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisp...
Dose intensity and prognosis in the neoadjuvant chemotherapy of osteosarcoma. A retrospective analys...
Dose intensity and prognosis in neoadjuvant chemotherapy for osteosarcoma - A retrospective analysi
Background: A dose response relationship for doxorubictn and cyclophosphamide has been suggested. In...
Purpose: The aim of this study was to compare the results in terms of histologic response to primary...
PURPOSE: The aim of this study was to compare the results in terms of histologic response to prim...
Introduction: osteosarcoma is the most common primary bone tumor in children and young adults and ap...
Objectives: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intend...
Objectives: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intend...
Purpose: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven ...
Objective: In this study, we describe experiences with gemcitabine–docetaxel combination therapy as ...